Hormonal
GLP-1 and dual GIP/GLP-1 receptor agonists exert neuropsychiatric effects by modulating central neurotransmitter systems (dopamine, serotonin, GABA, glutamate) and promoting neuroplasticity, potentially treating addiction, depression, and cognitive decline.
GLP-1 and dual agonists (like semaglutide and tirzepatide) do more than just suppress appetite; they interact with brain receptors that regulate mood, reward, and memory. While they are primarily prescribed for diabetes and weight loss, research suggests they may also help with conditions like addiction, depression, and cognitive decline by balancing neurotransmitters like dopamine and serotonin. However, patients should be aware that while serious psychiatric side effects are rare and not consistently linked to the drugs, isolated reports of mood changes exist, so monitoring mental health is recommended.
Evidence suggests that GLP-1 receptor activation across key brain regions involved in energy balance and reward modulates multiple neurotransmitter systems, including dopamine and serotonin, as well as glutamatergic and GABAergic transmission, thereby influencing behavior, affective processes, and cognitive function.
Why this rating
The paper is a review integrating preclinical and clinical evidence, noting mixed clinical outcomes (e.g., Parkinson's trial) and isolated adverse events.
Source
Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry
Ana Cristina Tudosie et al. · International Journal of Molecular Sciences · 2026
DOI 10.3390/ijms27083628
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →